Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Insights into Imaging
Published in: Insights into Imaging 2/2015

Open Access 01-04-2015 | Statement

Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)

Author: European Society of Radiology (ESR)

Published in: Insights into Imaging | Issue 2/2015

Login to get access

Abstract

The future of medicine lies in early diagnosis and individually tailored treatments, a concept that has been designated ‘personalised medicine’ (PM), which aims to deliver the right treatment to the right patient at the right time. Medical imaging has always been personalised and is fundamental to almost all aspects of PM. It is instrumental in solving clinical differential diagnoses. Imaging procedures are tailored to the clinical problem and patient characteristics. Screening for preclinical disease is done with imaging. Stratification based on imaging biomarkers can help identify individuals suited for preventive intervention. Treatment decisions are based on the in vivo visualisation of the location and extent of an abnormality, as well as the loco-regional physiological, biochemical and biological processes using structural and molecular imaging. Image-guided biopsy provides relevant tissue specimens for genetic/molecular characterisation. In addition, radiogenomics relate imaging biomarkers to these genetic and molecular features. Furthermore, imaging is essential to patient-tailored therapy planning, therapy monitoring and follow-up of disease, as well as targeting non-invasive or minimally invasive treatments, especially with the rise of theranostics. Radiologists need to be prepared for this new paradigm as it will mean changes in training, clinical practice and in research.
Key Points
• Medical imaging is a key component in personalised medicine
• Personalised prevention will rely on image-based screening programmes
• Anatomical, functional and molecular imaging biomarkers affect decisions on the type and intensity of treatment
• Treatment response assessment with imaging will improve personalised treatment
• Image-based invasive intervention integrates personalised diagnosis and personalised treatment
Literature
1.
European Society of Radiology (2011) Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging 2:621–630CrossRefPubMedCentral
2.
3.
4.
5.
Siegel CA, Melmed GY (2009) Predicting response to Anti-TNF Agents for the treatment of crohn’s disease. Therap Adv Gastroenterol 2:245–251PubMedCentralPubMed
6.
7.
8.
9.
Kondo H, Kanematsu M, Goshima S et al (2010) Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT: comparison of total body weight, lean body weight, and blood volume. Radiology 254:163–169CrossRefPubMed
10.
Liu J, Gao J, Wu R, Zhang Y, Hu L, Hou P (2013) Optimizing contrast medium injection protocol individually with body weight for high-pitch prospective ECG-triggering coronary CT angiography. Int J Cardiovasc Imaging 29:1115–1120CrossRefPubMed
11.
12.
Martin L, Ruddlesden R, Makepeace C, Robinson L, Mistry T, Starritt H (2013) Paediatric x-ray radiation dose reduction and image quality analysis. J Radiol Prot 33:621–633CrossRefPubMed
13.
14.
May MS, Deak P, Kuettner A et al (2012) Radiation dose considerations by intra-individual Monte Carlo simulations in dual source spiral coronary computed tomography angiography with electrocardiogram-triggered tube current modulation and adaptive pitch. Eur Radiol 22:569–578CrossRefPubMed
15.
Frellesen C, Stock W, Kerl JM et al (2014) Topogram-based automated selection of the tube potential and current in thoraco-abdominal trauma CT—a comparison to fixed kV with mAs modulation alone. Eur Radiol 24:1725–1734CrossRefPubMed
16.
Independent UKPoBCS (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380:1778–1786CrossRef
17.
Levine MS, Yee J (2014) History, evolution, and current status of radiologic imaging tests for colorectal cancer screening. Radiology 273:S160–S180CrossRefPubMed
18.
van Iersel CA, de Koning HJ, Draisma G et al (2007) Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 120:868–874CrossRefPubMed
19.
20.
van Klaveren RJ, Oudkerk M, Prokop M et al (2009) Management of lung nodules detected by volume CT scanning. N Engl J Med 361:2221–2229CrossRefPubMed
21.
Evangelista L, Panunzio A, Polverosi R, Pomerri F, Rubello D (2014) Indeterminate lung nodules in cancer patients: pretest probability of malignancy and the role of F-18-FDG PET/CT. American Journal of Roentgenology 202:507–514CrossRefPubMed
22.
Kavousi M, Elias-Smale S, Rutten JH et al (2012) Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 156:438–444CrossRefPubMed
23.
Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63:636–646CrossRefPubMed
24.
Saam T, Hetterich H, Hoffmann V et al (2013) Meta-analysis and systematic review of the predictive value of carotid plaque hemorrhage on cerebrovascular events by magnetic resonance imaging. J Am Coll Cardiol 62:1081–1091CrossRefPubMed
25.
Arias F, Chicata V, Garcia-Velloso MJ et al (2014) Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer. Clin Transl Oncol. doi:10.​1007/​s12094-014-1204-8
26.
27.
De Leyn P, Dooms C, Kuzdzal J et al (2014) Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 45:787–798CrossRefPubMed
28.
Silvestri GA, Gonzalez AV, Jantz MA et al (2013) Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e211S–250SCrossRefPubMed
29.
30.
Czernin J, Allen-Auerbach M, Schelbert HR (2007) Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 48(Suppl 1):78S–88SPubMed
31.
Kostakoglu L, Cheson BD (2014) Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging 41:1004–1027CrossRefPubMed
32.
van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393CrossRefPubMed
33.
Steiner T, Juvela S, Unterberg A et al (2013) European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 35:93–112CrossRefPubMed
34.
Moll FL, Powell JT, Fraedrich G et al (2011) Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 41(Suppl 1):S1–S58CrossRefPubMed
35.
Rothwell PM, Gutnikov SA, Warlow CP, European Carotid Surgery Trialist’s C (2003) Reanalysis of the final results of the European Carotid Surgery Trial. Stroke 34:514–523CrossRefPubMed
36.
Mowatt G, Scotland G, Boachie C et al (2013) The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technol Assess 17:1–281CrossRefPubMed
37.
Cornelis F, Rigou G, Le Bras Y et al (2013) Real-time contrast-enhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings. Radiology 269:159–166CrossRefPubMed
38.
39.
Balu-Maestro C, Ianessi A, Chapellier C, Marcotte C, Stolear S (2013) Ultrasound-guided lymph node sampling in the initial management of breast cancer. Diagn Interv Imaging 94:389–394CrossRefPubMed
40.
Monfardini L, Preda L, Aurilio G et al (2014) CT-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures. Radiol Med 119:852–860CrossRefPubMed
41.
van den Brekel MW, Castelijns JA (2005) What the clinician wants to know: surgical perspective and ultrasound for lymph node imaging of the neck. Cancer Imaging 5(Spec No A):S41–49CrossRefPubMedCentralPubMed
42.
Nakajima N, Kataoka M, Sugawara Y et al (2013) Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 87:738–746CrossRefPubMed
43.
Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U (2013) Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging 3:272–281PubMedCentralPubMed
44.
Fournier LS, Oudard S, Thiam R et al (2010) Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 256:511–518CrossRefPubMed
45.
Mannelli L, Patterson AJ, Zahra M et al (2010) Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. AJR Am J Roentgenol 195:524–527CrossRefPubMed
46.
de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50(Suppl 1):43S–54SCrossRefPubMed
47.
Kyriazi S, Collins DJ, Messiou C et al (2011) Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging–value of histogram analysis of apparent diffusion coefficients. Radiology 261:182–192CrossRefPubMed
48.
49.
50.
Hricak H (2011) Oncologic imaging: a guiding hand of personalized cancer care. Radiology 259:633–640CrossRefPubMed
51.
Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M (2006) Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80:151–156CrossRefPubMed
52.
Hugonnet F, Fournier L, Medioni J et al (2011) Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18 F-fluoromisonidazole PET/CT study. J Nucl Med 52:1048–1055CrossRefPubMed
53.
Eschmann SM, Paulsen F, Reimold M et al (2005) Prognostic impact of hypoxia imaging with 18 F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46:253–260PubMed
54.
55.
Sparchez Z, Radu P, Zaharia T et al (2011) Usefulness of contrast enhanced ultrasound guidance in percutaneous biopsies of liver tumors. J Gastrointestin Liver Dis 20:191–196PubMed
56.
Pirotte B, Goldman S, Salzberg S et al (2003) Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg 38:146–155CrossRefPubMed
57.
Fei B, Nieh PT, Schuster DM, Master VA (2013) PET-directed, 3D Ultrasound-guided prostate biopsy. Diagn Imaging Eur 29:12–15PubMedCentralPubMed
58.
Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51CrossRefPubMed
59.
Wangler C, Buchmann I, Eisenhut M, Haberkorn U, Mier W (2007) Radiolabeled peptides and proteins in cancer therapy. Protein Pept Lett 14:273–279CrossRefPubMed
60.
61.
de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN (2008) Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 44:551–556CrossRefPubMed
62.
Postema EJ, McEwan AJ (2009) Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults. Cancer Biother Radiopharm 24:519–525CrossRefPubMed
63.
van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5:382–393CrossRefPubMed
64.
65.
Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA (2008) Tumor receptor imaging. J Nucl Med 49(Suppl 2):149S–163SCrossRefPubMed
66.
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M (2007) Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging 51:152–163PubMed
67.
Kim MJ, Jang DH, Lee YI, Jung HS, Lee HJ, Choa YH (2011) Preparation, characterization, cytotoxicity and drug release behavior of liposome-enveloped paclitaxel/Fe3O4 nanoparticles. J Nanosci Nanotechnol 11:889–893CrossRefPubMed
68.
Kono K, Nakashima S, Kokuryo D et al (2011) Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials 32:1387–1395CrossRefPubMed
69.
Hong SY, Tobias G, Al-Jamal KT et al (2010) Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging. Nat Mater 9:485–490CrossRefPubMed
70.
Kuo MD, Jamshidi N (2014) Behind the numbers: Decoding molecular phenotypes with radiogenomics–guiding principles and technical considerations. Radiology 270:320–325CrossRefPubMed
71.
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006PubMedCentralPubMed
72.
Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 70:232–241CrossRefPubMed
73.
Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRefPubMed
74.
Diehn M, Nardini C, Wang DS et al (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 105:5213–5218CrossRefPubMedCentralPubMed
75.
Zinn PO, Mahajan B, Sathyan P et al (2011) Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One 6:e25451CrossRefPubMedCentralPubMed
76.
Jamshidi N, Diehn M, Bredel M, Kuo MD (2014) Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology 270:1–2CrossRefPubMed
77.
Yamamoto S, Maki DD, Korn RL, Kuo MD (2012) Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. AJR Am J Roentgenol 199:654–663CrossRefPubMed
78.
Karlo CA, Di Paolo PL, Chaim J et al (2014) Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 270:464–471CrossRefPubMedCentralPubMed
79.
Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R (2014) NF-kappaB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer 83:189–196CrossRefPubMedCentralPubMed
80.
Kuo MD, Yamamoto S (2011) Next generation radiologic-pathologic correlation in oncology: Rad-Path 2.0. AJR Am J Roentgenol 197:990–997CrossRefPubMed
81.
Salavati A, Basu S, Heidari P, Alavi A (2009) Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nucl Med Commun 30:95–116CrossRefPubMed
82.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
83.
Carnaghi C, Sclafani F, Basilico V, Doherty M (2011) Response assessment in oncology: limitations of anatomic response criteria in the era of tailored treatments. Q J Nucl Med Mol Imaging 55:589–602PubMed
84.
Ford R, Schwartz L, Dancey J et al (2009) Lessons learned from independent central review. Eur J Cancer 45:268–274CrossRefPubMed
85.
Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582CrossRefPubMed
86.
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
87.
Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE (2002) CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 225:416–419CrossRefPubMed
88.
Shah GD, Kesari S, Xu R et al (2006) Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol 8:38–46CrossRefPubMedCentralPubMed
89.
Frauenfelder T, Tutic M, Weder W et al (2011) Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J 38:162–168CrossRefPubMed
90.
Buckler AJ, Mozley PD, Schwartz L et al (2010) Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. Acad Radiol 17:107–115CrossRefPubMed
91.
Liu F, Zhao B, Krug LM et al (2010) Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol 5:879–884CrossRefPubMed
92.
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefPubMedCentralPubMed
93.
Nunn AD (2007) Molecular imaging and personalized medicine: an uncertain future. Cancer Biother Radiopharm 22:722–739CrossRefPubMed
94.
Eckelman WC, Reba RC, Kelloff GJ (2008) Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 13:748–759CrossRefPubMed
95.
Padhani AR, Miles KA (2010) Multiparametric imaging of tumor response to therapy. Radiology 256:348–364CrossRefPubMed
96.
Dunnwald LK, Gralow JR, Ellis GK et al (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457CrossRefPubMedCentralPubMed
97.
98.
99.
Smits M, Vernooij MW, Wielopolski PA, Vincent AJ, Houston GC, van der Lugt A (2007) Incorporating functional MR imaging into diffusion tensor tractography in the preoperative assessment of the corticospinal tract in patients with brain tumors. AJNR Am J Neuroradiol 28:1354–1361CrossRefPubMed
100.
101.
Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J (2011) Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 101:369–375CrossRefPubMedCentralPubMed
102.
Crommelin DJ, Storm G, Luijten P (2011) ‘Personalised medicine’ through ‘personalised medicines’: time to integrate advanced, non-invasive imaging approaches and smart drug delivery systems. Int J Pharm 415:5–8CrossRefPubMed
103.
Moonen CT (2007) Spatio-temporal control of gene expression and cancer treatment using magnetic resonance imaging-guided focused ultrasound. Clin Cancer Res 13:3482–3489CrossRefPubMed
104.
105.
106.
107.
108.
Metadata
Title
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)
Author
European Society of Radiology (ESR)
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Insights into Imaging / Issue 2/2015
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1007/s13244-015-0394-0

Other articles of this Issue 2/2015

Insights into Imaging 2/2015 Go to the issue

Report

The ESR Patient Advisory Group (ESR-PAG)

Pictorial Review

MDCT of blunt renal trauma: imaging findings and therapeutic implications

Statement

Magnetic Resonance Fingerprinting - a promising new approach to obtain standardized imaging biomarkers from MRI

Pictorial Review

Role of interventional radiology in the management of complications after pancreatic surgery: a pictorial review

Opinion

Research education in Europe: an opinion paper by the European Society of Radiology

Review

The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review